


EXHIBIT B

)

Keith Rubner



ANTONIO ENCHALAN, et al.; WIES KIM, et al.; HANG QAO

CASE NO.: 2:21-cv-00861-TSZ

individually and on behalf of all others similarly situated,
v.
ATHIRA PHARMA, INC., et al.,(Consolidated with Case Nos. 21-cv-00862-TSZ
and 21-cv-00864-TSZ)Plaintiffs,
Defendants.**SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) FINAL APPROVAL HEARING; AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEES AND PAYMENT OF LITIGATION EXPENSES****TO: All persons and entities who or which purchased or otherwise acquired Athira Pharma, Inc. ("Athira") publicly traded common stock during the period from September 17, 2020, through June 17, 2021, inclusive (the "Class Period"), and were damaged thereby (the "Class"):****PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION SETTLEMENT**

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure, that the above-captioned litigation (the "Action") has been certified as a class action for settlement purposes, except for certain persons and entities who are excluded from the Class by definition as explained in the full printed Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Final Approval Hearing; and (III) Motion for an Award of Attorneys' Fees and Payment of Litigation Expenses (the "Notice"), available at www.AthiraSecuritiesSettlement.com.

YOU ARE ALSO NOTIFIED that Plaintiffs in the Action have reached a proposed settlement of the Action for \$10,000,000 in cash (the "Settlement"), which, if approved, will resolve all claims in the Action and related claims.

A hearing will be held **on October 25, 2024 at 10:00 a.m.**, before the Honorable Thomas S. Zilly, United States District Court for the Western District of Washington, at the United States Courthouse, Courtroom 15206, 700 Stewart Street, Seattle, WA 98101, to determine: (i) whether the proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Amended Stipulation and Agreement of Settlement dated December 15, 2023 (and in the Notice) should be approved; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Co-Lead Counsel's application for an award of attorneys' fees and payment of expenses should be approved.

If you are a member of the Class, your rights will be affected and you may be entitled to share in the Settlement Fund. If you have not yet received the Notice, Proof of Claim Form ("Claim Form"), and Exclusion Request (Opt-Out) Form, you may obtain copies by contacting the Settlement Administrator at *Athira Pharma Securities Litigation*, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson Street, Suite 205, Media, PA 19063, (866) 274-4004. Copies can also be downloaded from the website www.AthiraSecuritiesSettlement.com.

If you are a member of the Class, to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form to the Settlement Administrator *postmarked* (or bearing other proof of mailing) **no later than September 6, 2024**, if sent by mail, or *submitted online* at www.AthiraSecuritiesSettlement.com **no later than September 6, 2024**. If you are a member of the Class, you do not exclude yourself from the Class, and you do not submit a proper Claim Form, you will not be eligible to share in the distribution of the net proceeds of the Settlement but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

If you are a member of the Class and wish to exclude yourself from the Class, you must submit a request for exclusion to the Settlement Administrator **no later than September 6, 2024** by following the instructions in the Notice. If you properly exclude yourself from the Class, you will not be bound by any judgments or orders entered by the Court in the Action and you cannot share in the proceeds of the Settlement.

Any objections to the proposed Settlement, the proposed Plan of Allocation (including the *cy pres* recipient), or Co-Lead Counsel's motion for attorneys' fees and payment of expenses, must either be mailed to the Settlement Administrator *postmarked* (or bearing other proof of mailing) **no later than September 6, 2024** (if you are *not* represented by an attorney), or **no later than October 11, 2024** (if you are represented by an attorney), or be presented to the Court by attending the Settlement Hearing, according to the instructions in the Notice.

Please do not contact the Court, the Clerk's Office, Athira, or other Defendants, or their counsel. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Co-Lead Counsel or the Settlement Administrator.

Inquiries, other than requests for the Notice, Claim Form, and Exclusion Request (Opt-Out) Form, should be made to Co-Lead Counsel:

GLANCY PRONGAY & MURRAY LLP
Casey E. Sadler, Esq.
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Telephone: (888) 773-9224
Email: settlements@glancylaw.com

LABATON KELLER SUCHAROW LLP
Michael P. Canty, Esq.
140 Broadway
New York, New York 10005
Telephone: (888) 219-6877
Email: settlementquestions@labaton.com

Requests for the Notice, Claim Form, and Exclusion Request (Opt-Out) Form should be made to:

Athira Pharma Securities Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson Street, Suite 205
Media, PA 19063
(866) 274-4004
info@strategicclaims.net
www.AthiraSecuritiesSettlement.com

MUTUAL FUND PERFORMANCE

WEEK OF JUNE 10, 2024 A13

INVESTORS.COM

36 Mo Performance Rating	Fund	YTD 12Wk % Chg	12Wk % Chg	5 Yr Tax Rtn	Net Value	NAV
--------------------------------	------	-------------------	---------------	-----------------	--------------	-----

-M-N-O-

MainStay Fds						
A-17 bil 800-624-6782						
A- Filt Rate	+4 +2 +2			8.89	0.00	

MainStay Fds A						
A-8.4 bil 800-624-6782						
B- MKH FY CB	+3 +2 +1			5.16	0.00	

A- VMCM EdC	+7 +1 +8			36.69	-0.17	
A- VMCM Val	+4 +1 +7			28.05	-0.11	
A- Winslow LCG	+16 +2 +10			10.41	-0.01	

MainStay Fds I						
A-3.0 bil 800-624-6782						
A- Epoch Gl Eq	+9 +4 +5			22.59	0.00	

A- SPS900 ldx	+13 +4 +9			59.52	-0.01	
Mairs&Power						
A-6.3 bil 800-304-7044						

A-8PowerGrowth+13+4+9				165.56	0.25	
Marsico Funds						
A-1.6 bil 888-860-8686						

A- Foc	+20 +5 +13			27.89	-0.01	
A- Grow	+20 +5 +12			24.60	-0.04	
Mass Mutual						

A-3.1 bil 888-309-3539						
A- Bl Ch	+18 +5 +10			23.48	0.06	
MassMutual Select						

A-12.4 bil 888-309-3539						
A- Eq Op	+6 +2 +8			18.24	0.00	
A- Fnd V	+9 +2 +8			9.18	-0.03	

A- MCG	+4 +4 +6			20.53	0.10	
A- SPS900	+13 +4 +10			17.22	0.00	
Matthews Asian Funds						

A-2.8 bil 800-789-2742						
A- India	+7 +0 +7			28.11	-0.02	
Mercury Funds A						

A-208 mil 888-546-9518						
A- HouseGrowth+18+4+11				77.49	0.13	
Metropolitan West						

A-51.9 bil 800-241-4671						
A- Fltng Rt In	+5 +3 +2			9.53	0.01	
A- Total Rtn	+0 +0 +10			8.98	0.00	

A- Uncons Bd	+2 +1 +0			10.27	0.01	
MFS Funds A						
A-57.3 bil 800-225-2606						

B- AggrGrAlloc	+8 +2 +5			30.11	0.00	
A- Core Equity	+11 +2 +8			50.34	-0.04	
A- Corp Bond	+1 +1 +0			12.29	0.00	

A- IntlntnrlVal	+10 +4 +4			41.11	0.13	
A- MassInvGrt	+10 +3 +9			43.43	-0.07	
A- Mass InvHlgr	+2 +1 +1			7.35	0.02	

A- Muni Income	+1 +0 +1			8.16	0.03	
A- Technology	+21 +3 +10			62.91	-0.11	
A- TotRetBd	+0 +0 +10			9.42	0.00	

A- TotalReturn	+4 +2 +4			19.65	-0.04	
B- Utilities	+6 +10 +3			22.06	-0.17	
MFS Funds I						

A-55.3 bil 800-225-2606						
A- Growth	+21 +5 +11			208.07	-0.53	
A- Intl Equity	+8 +3 +6			35.69	0.16	

A- MidCapGrowth	+7 +3 +7			30.94	-0.22	
A- MidCapValue	+7 +1 +8			32.90	0.13	
A- Research	+11 +2 +9			61.11	-0.02	

A- Value	+7 +2 +7			50.85	-0.05	
Morgan Stanley Inst						
A-174 bil 800-548-7786						

B- Gl Fr	+4 +2 +6			35.58	0.17	
E- Growth	-2 -7 +3			33.75	0.22	
MorganStanleyPFS						

A-5.3 bil 888-673-9950						
E- Core Fl	+1 +0 +1.0			6.76	0.00	
A- LgtRetBd	+11 +3 +8			24.25	-0.01	

MuhlenKmp						
A-230 mil 800-860-3863						
A- Fund	+8 +4 +10			67.01	-0.10	

Munder Funds						
A-2.7 bil 800-539-3863						
D- Intl SmCp	+8 +4 +4			15.71	0.01	

Munder Funds CI A						
A-824 mil 800-539-3863						
A- Multi-Cap	+13 +3 +8			53.46	-0.06	

Nationwide Fds R6						
A-1.4 bil 800-948-0920						
A- BWMV DUSC	+12 +4 +10			15.45	-0.01	

Nationwide Funds						
A-907 mil 800-848-0920						
A- SGP 500	+13 +4 +10			25.58	-0.01	

Natixis Funds						
A-22.5 bil 800-225-5478						
D- Inv G6	+1 +1 +1			9.82	0.00	

A- LS Growth	+15 +3 +11			26.66	0.13	
A- Oakmark	+5 +0 +10			28.55	0.02	
A- US Eq Opp	+9 +1 +9			40.04	0.14	

Neuberger Berman Fds						
A-28.8 bil 800-366-6264						
B- LngSh	+3 +1			17.92	0.02	

A- FloatRtInc	+4 +2 +3			9.45	0.01	
C- LC Value	+8 +4 +8			44.46	0.16	
C- Str Inc	+2 +1 +1			9.77	0.00	

A- Sus Eqty	+14 +4 +10			45.77	0.09	
Neuberger Berman Inv						
A-7.4 bil 800-877-9700						

A- Guardian	+12 +3 +12			27.89	0.05	
Neuberger Berman Tr						
A-5.7 bil 800-877-9700						

C- Genesis	+2 -1 +6			62.42	-0.45	
New Covenant Funds						
A-1.3 bil 877-835-4531						

A- Growth	+11 +3 +9			63.19	-0.05	
Nicholas Group						
A-5.8 bil 800-654-5447						

A- Fund	+6 +0 +11			89.99	-3.8	
Northen Funds						
A-34.6 bil 800-595-9111						

E- Bond Index	+0 +0 +1.0			9.11	0.00	
E- EM Eq ldx	+6 +5 +0			11.33	0.08	
C- Ht Fnd ldx	+2 +1 +2			5.95	0.00	

A- Bt Intl ldx	+9 +3 +4			15.06	0.05	
A- Lgt Cap Core	+14 +4 +10			27.87	-0.02	
A- Mid Cap ldx	+16 +0 +7			21.24	-0.06	

A- Stock ldx	+13 +4 +10			55.12	-0.01	
Nuveen Funds A						
A-14.7 bil 800-257-8787						

E- All-Am Muni	+1 +0 +0			10.18	0.04	
A- Div Value	+8 +3 +4			14.89	-0.03	
Nuveen Funds I						

A-9.1 bil 800-257-8787						
D- HY Muni	+4 +2 +2			15.14	0.07	
D- IntlMuni	+1 +0 +2			8.87	0.03	

C- LdtMuni	+1 +0 +2			10.92	0.02	
A- MidCapValue	+6 +2 +7			55.03	-0.26	
A- MultiCapVal	+8 +4 +8			50.78	-0.12	

Oak Associates Funds						
A-36 Mo Performance						
Rating	Fund	YTD 12Wk % Chg	12Wk % Chg	5 Yr Tax Rtn	Net Value	NAV Chg

36 Mo Performance Rating	Fund	YTD 12Wk % Chg	12Wk % Chg	5 Yr Tax Rtn	Net Value	NAV
--------------------------------	------	-------------------	---------------	-----------------	--------------	-----

A-1.2 bil 888-462-5386						
A- OakTechnolo	+18 +4 +11			46.49	-0.08	
A- OakSelectGr	+10 +7 +8			148.79	0.15	

Oakmark Funds Invest						
A-22.1 bil 800-625-6275						
B- Eqty & Inc	+3 +1 +6			34.65	0.04	

A- Fund	+5 +0 +11			139.64	0.07	
D- Internatl	+2 +3 +3			27.27	0.16	
B- Overseas	-1 -2 +9			69.88	0.15	

Oberweis Funds						
A-952 mil 800-245-7311						
A- Micro Cap	+9 +6 +12			41.98	-0.35	

Oberweis:SmCap Opp						
A-514 mil 800-245-7311						
A- Sm-Cap Opp	+14 +5 +13			25.80	-0.34	

Old Westbury Fds						
A-8.1 bil 800-607-2200						
A- All Cp Core	+2 +1 +9			25.72	-0.04	

D- Credit Inc	+1 +1			8.05	0.01	
D- Fnd ldx	+0 +0 +0			10.10	0.01	
D- LC Strat	+13 +4 +6			19.54	0.00	

D- Muni Bd	-1 -1 +1			11.47	0.04	
E- Sm&Mid Cp Stk	+0 +3			15.95	-0.02	
Optimum Funds Inst						

A-8.1 bil 800-914-0278						
E- Fnd ldx	+0 +0 +1.0			8.19	0.00	
A- Lgt Cap Gro	+18 +5 +9			23.59	-0.01	

A- Lgt Cap Val	+8 +2 +7			18.83	-0.02	
Parnassus Fds						
A-13.9 bil 800-999-3505						

A- Core Eqty	+10 +2 +10			60.28	0.00	
Pear Tree						
A-4.4 bil 800-326-2151						

D- Foreign V	+5 +4 +3			24.21	0.09	
Perm Port Funds						
A- Perm	+10 +6 +7			56.39	0.32	

PGIM Funds A						
A-16.9 bil 800-225-1852						
C- High Yield	+2 +1 +1			4.70	-0.01	

D- Tot Rtn Bnd	+1 +0 +1.0			11.92	0.00	
PGIM Jenn Funds A						
A-16.9 bil 800-225-1852						

A- Jenn Blend	+10 +1 +7			24.51	-0.04	
A- JennDvstGr	+20 +2 +10			19.41	0.02	
A- Jenn Foc	+19 +3 +9			24.19	0.04	

A- Jenn Growth	+17 +11			59.83	0.13	
A- JennHealths	+11 +2 +8			40.11	-0.07	
A- JennHlgr	+11 +11			56.73	0.60	

A- JennUtility	+13 +14 +2			14.52	-0.20	
A- Jenn Value	+10 +2 +6			22.06	-0.03	
PGIM Quant Funds A						

sevans@strategicclaims.net

From: phhubs@prnewswire.com
Sent: Monday, June 10, 2024 8:00 AM
To: sevans@strategicclaims.net
Subject: PR Newswire: Press Release Distribution Confirmation for Glancy Prongay & Murray LLP.
ID#4176872-1-1

Hello

Your press release was successfully distributed at: 10-Jun-2024 08:00:00 AM ET

Release headline: Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. – (NASDAQ: ATHA)
Word Count: 877
Product Selections:
US1
Visibility Reports Email
Complimentary Press Release Optimization
PR Newswire ID: 4176872-1-1

View your release:* https://www.prnewswire.com/news-releases/glancy-prongay--murray-llp-and-labaton-keller-sucharow-llp-announce-proposed-class-action-settlement-on-behalf-of-purchasers-of-the-publicly-traded-common-stock-of-athira-pharma-inc--nasdaq-atha-302160652.html?tc=eml_cleartime

Thank you for choosing PR Newswire!

Regards,

Your 24/7 Content Services Team
888-776-0942
PRNCS@prnewswire.com

Achieve your communications goals every time you distribute content, with these tips for crafting your next perfect press release: <https://www.cision.com/us/resources/tip-sheets/easy-pr-sharing-guide/?sf=false>

US Members, find audience, engagement and other key metrics for your release by accessing your complimentary Visibility Reports in the Online Member Center: <https://portal.prnewswire.com/Login.aspx>

* If the page link does not load immediately, please refresh and try again after a few minutes.